← Back to Search

Levocarnitine for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma

Phase 3
Recruiting
Led By Etan Orgel
Research Sponsored by Children's Oncology Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 years
Awards & highlights

Study Summary

This trial will test if adding levocarnitine to chemo helps protect the liver in leukemia/lymphoma patients.

Who is the study for?
This trial is for young adults aged 15-39 with newly diagnosed B-ALL, T-ALL, lymphoblastic lymphoma, or MPAL. They must have liver function within certain limits and plan to receive asparaginase chemotherapy. Excluded are those with Down syndrome, inherited/autoimmune liver diseases, severe liver fibrosis, prior malignancy treatments (except specific allowed cases), pregnant or breastfeeding women, and those not using effective contraception.Check my eligibility
What is being tested?
The study tests if Levocarnitine added to standard chemotherapy can protect the liver from damage caused by asparaginase in leukemia/lymphoma patients. It compares outcomes of patients receiving Levocarnitine plus chemotherapy against those receiving only standard chemo.See study design
What are the potential side effects?
Levocarnitine may cause nausea, vomiting, abdominal cramps, diarrhea and a 'fishy' body odor. As it's being used alongside chemotherapy drugs like pegaspargase which can cause liver issues among other side effects; monitoring will be crucial.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of conjugated hyperbilirubinemia >3 mg/dL during induction therapy
Secondary outcome measures
Alanine Transaminase
Incidence of minimal residual disease (MRD) positivity (MRD >= 0.01%)
Other outcome measures
Adherence to oral levocarnitine during induction chemotherapy measured by percentage of pills returned relative to those prescribed
Levocarnitine
Asparaginase activity
+14 more

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Arm C (rescue levocarnitine)Experimental Treatment1 Intervention
Patients in Arms A and B who develop conjugated hyperbilirubinemia > 3 mg/dL during induction may receive levocarnitine rescue PO or IV supplementation until resolution of conjugated hyperbilirubinemia =< 3 mg/dL (or start of consolidation or the next treatment phase, whichever occurs first).
Group II: Arm A (levocarnitine, standard of care chemotherapy)Experimental Treatment5 Interventions
Patients receive levocarnitine PO or IV prior to standard of care induction chemotherapy with pegaspargase or calaspargase pegol on study. Patients may also undergo blood sample collection during screening and on study.
Group III: Arm B (standard of care chemotherapy)Active Control4 Interventions
Patients receive standard of care induction chemotherapy with pegaspargase or calaspargase pegol on study. Patients may also undergo blood sample collection during screening and on study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 2
~1700
Levocarnitine
1996
Completed Phase 3
~510
Pegaspargase
2005
Completed Phase 3
~9010

Find a Location

Who is running the clinical trial?

Children's Oncology GroupLead Sponsor
454 Previous Clinical Trials
237,500 Total Patients Enrolled
Etan OrgelPrincipal InvestigatorChildren's Oncology Group

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What criteria must I meet to partake in this scientific investigation?

"Prospective enrollees of this clinical study should have been diagnosed with acute lymphoblastic leukemia and be within the age range of 15 to 40 years old. This trial is expected to accept around 440 participants in total."

Answered by AI

Is the age criteria for this research limited to individuals older than 40?

"This clinical trial is recruiting 15-40 year-olds, while 638 trials are available for adolescents and 2449 studies accept participants aged over 65."

Answered by AI

Are any of the medical centers conducting this research located in North America?

"This medical trial is recruiting patients from Golisano Children's Hospital of Southwest Florida in Fort Myers, Florida, Nemours Children's Clinic - Jacksonville in Jacksonville, Indiana and Riley Hospital for Children in Indianapolis, Michigan as well as other 26 sites."

Answered by AI

How many participants has this study enrolled thus far?

"This clinical trial necessitates 440 patients that meet the eligibility criteria. Patients may be signed up from various medical institutions around the country, such as Golisano Children's Hospital of Southwest Florida in Fort Myers and Nemours Children's Clinic - Jacksonville in Indiana."

Answered by AI

Are there any vacancies for participants in this clinical experiment?

"Clinicaltrials.gov attests that this trial is in the midst of participant recruitment, with a first post date on August 14th 2023 and an updated listing as recent as August 31st 2023."

Answered by AI

To what degree can Arm C (rescue levocarnitine) harm individuals?

"The safety of Arm C (rescue levocarnitine) has been assessed by our Power team with a score of 3. This demonstrates that past trials have yielded promising results in terms efficacy, as well as several iterations proving the drug's safety."

Answered by AI

Who else is applying?

What site did they apply to?
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
2023. "Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05602194.
All > Toronto > Fargo
~293 spots leftby Dec 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top